Effects of trimetazidine in patients with severe chronic heart failure with reduced left ventricular ejection fraction: A prospective, randomized, open-label, cross-over study.
Michał BohdanIwona StopczyńskaPiotr WiśniewskiJoanna MoryśPiotr NiedoszytkoMarcin GruchałaPublished in: Cardiology journal (2020)
The additional use of TMZ on top of standard medical therapy in stable advanced HFrEF patients was not associated with significant changes in mortality, exercise capacity, LVEF, or quality of life.
Keyphrases
- ejection fraction
- aortic stenosis
- left ventricular
- open label
- end stage renal disease
- healthcare
- clinical trial
- heart failure
- chronic kidney disease
- newly diagnosed
- physical activity
- high intensity
- type diabetes
- squamous cell carcinoma
- mesenchymal stem cells
- prognostic factors
- radiation therapy
- study protocol
- cardiovascular disease
- phase ii study
- hypertrophic cardiomyopathy
- percutaneous coronary intervention
- cell therapy
- patient reported outcomes
- phase iii